Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180975 | 0.85 | GRIN2B (0.37) | GRIN2B | |
| SCHEMBL1960953 | 0.84 | HCRTR1 (0.38) | HCRTR1HCRTR2HTR2CALDH1A1TSHR | |
| SCHEMBL3187760 | 0.82 | GRIN2B (0.37) | GRIN2B | |
| SCHEMBL3542557 | 0.82 | GRIN2B (0.39) | GRIN2B | |
| SCHEMBL4057266 | 0.81 | HCRTR1 (0.35) | HCRTR1HCRTR2HTR2CGRIN2BALDH1A1 | |
| SCHEMBL1959767 | 0.78 | CXCR2 (0.46) | ALDH1A1 | |
| SCHEMBL1962134 | 0.77 | CXCR2 (0.39) | ALDH1A1 | |
| SCHEMBL1958382 | 0.77 | CXCR2 (0.38) | ALDH1A1 | |
| SCHEMBL1961648 | 0.77 | CXCR2 (0.40) | ALDH1A1 | |
| SCHEMBL1960349 | 0.77 | MEN1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161273-B1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV (BE) | 2015-04-15 | — | — | EP | claimed |
| EP-2161273-B1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV (BE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2546254-A1 | Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2013-01-16 | — | — | EP | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2161273-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2010-03-10 | — | — | EP | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | HCRTR1 3673/4885HCRTR2 4426/4885HTR2C 1685/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | HCRTR1 3430/4885HCRTR2 4115/4885HTR2C 2270/4885 |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | CYP3A5, TPMT, TYMP | HCRTR1 3595/4885HCRTR2 4318/4885HTR2C 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.